GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hayat Pharmaceutical Industries Co (AMM:HPIC) » Definitions » YoY EBITDA Growth

Hayat Pharmaceutical Industries Co (AMM:HPIC) YoY EBITDA Growth : 25.00% (As of Mar. 2025)


View and export this data going back to 2006. Start your Free Trial

What is Hayat Pharmaceutical Industries Co YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Hayat Pharmaceutical Industries Co's YoY EBITDA Growth for the quarter that ended in Mar. 2025 was 25.00%.

Hayat Pharmaceutical Industries Co's EBITDA per Share for the three months ended in Mar. 2025 was JOD0.09.


Hayat Pharmaceutical Industries Co YoY EBITDA Growth Historical Data

The historical data trend for Hayat Pharmaceutical Industries Co's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hayat Pharmaceutical Industries Co YoY EBITDA Growth Chart

Hayat Pharmaceutical Industries Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.68 14.05 -0.89 -24.86 22.06

Hayat Pharmaceutical Industries Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.00 825.00 -58.54 29.33 25.00

Hayat Pharmaceutical Industries Co YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Hayat Pharmaceutical Industries Co's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (A: Dec. 2024 )
=(EBITDA per Share (A: Dec. 2024 )-EBITDA per Share (A: Dec. 2023 ))/ | EBITDA per Share (A: Dec. 2023 ) |
=(0.509-0.417)/ | 0.417 |
=22.06 %

Hayat Pharmaceutical Industries Co's YoY EBITDA Growth for the quarter that ended in Mar. 2025 is calculated as:

YoY EBITDA Growth (Q: Mar. 2025 )
=(EBITDA per Share (Q: Mar. 2025 )-EBITDA per Share (Q: Mar. 2024 )) / | EBITDA per Share (Q: Mar. 2024 )) |
=(0.09-0.072)/ | 0.072 |
=25.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hayat Pharmaceutical Industries Co YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Hayat Pharmaceutical Industries Co's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Hayat Pharmaceutical Industries Co Business Description

Traded in Other Exchanges
N/A
Address
Nile St. Al-Rajeeb, P.O. Box 1564, Amman, JOR, 11118
Hayat Pharmaceutical Industries Co is a Jordan based pharmaceutical manufacturing company. Its principal activity is producing human and veterinary in all its forms and medical stickers and stockings. The company is also involved in the production of medical supplies, body care lotions, cosmetics, and initiating marketing campaigns as well as import and export operations. It has developed and registered a hundred sixteen different dosage forms/pack sizes in the Jordan market representing fifty six different brands (molecules) in various therapeutic areas. Its products include Cardiovascular system, Infectious disease Dermatology, Gastrointestinal system, and Respiratory system.

Hayat Pharmaceutical Industries Co Headlines

No Headlines